PubMed:19759529 / 891-1151 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T6","span":{"begin":0,"end":260},"obj":"Sentence"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T5","span":{"begin":219,"end":223},"obj":"OrganismTaxon"}],"attributes":[{"id":"A5","pred":"db_id","subj":"T5","obj":"NCBItxid:10095"},{"id":"A6","pred":"db_id","subj":"T5","obj":"NCBItxid:10088"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-entities","denotations":[{"id":"6463","span":{"begin":81,"end":90},"obj":"ChemicalEntity"},{"id":"6464","span":{"begin":129,"end":142},"obj":"DiseaseOrPhenotypicFeature"},{"id":"6465","span":{"begin":181,"end":192},"obj":"ChemicalEntity"},{"id":"6466","span":{"begin":197,"end":203},"obj":"ChemicalEntity"},{"id":"6467","span":{"begin":219,"end":223},"obj":"OrganismTaxon"},{"id":"6468","span":{"begin":229,"end":237},"obj":"GeneOrGeneProduct"},{"id":"6469","span":{"begin":250,"end":253},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A17","pred":"db_id","subj":"6463","obj":"-1"},{"id":"A18","pred":"db_id","subj":"6464","obj":"MESH:D006948"},{"id":"A19","pred":"db_id","subj":"6465","obj":"MESH:D000661"},{"id":"A20","pred":"db_id","subj":"6466","obj":"MESH:D016291"},{"id":"A21","pred":"db_id","subj":"6467","obj":"NCBITaxon:10090"},{"id":"A22","pred":"db_id","subj":"6468","obj":"NCBIGene:14810"},{"id":"A23","pred":"db_id","subj":"6469","obj":"NCBIGene:13162"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T23","span":{"begin":62,"end":66},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":219,"end":223},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":229,"end":233},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":234,"end":237},"obj":"GeneOrGeneProduct"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T17","span":{"begin":62,"end":66},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":229,"end":233},"obj":"GeneOrGeneProduct"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T3","span":{"begin":129,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"originalLabel","subj":"T3","obj":"DISEASE"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T3","span":{"begin":129,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"DISEASE"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T3","span":{"begin":129,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"#label","subj":"T3","obj":"DISEASE"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T28","span":{"begin":81,"end":90},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":181,"end":192},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":197,"end":203},"obj":"ChemicalEntity"},{"id":"T32","span":{"begin":229,"end":233},"obj":"ChemicalEntity"},{"id":"T34","span":{"begin":250,"end":253},"obj":"ChemicalEntity"}],"attributes":[{"id":"A28","pred":"ID:","subj":"T28","obj":"ChemicalEntity"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000661"},{"id":"A30","pred":"ID:","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_2679"},{"id":"A31","pred":"ID:","subj":"T31","obj":"D016291"},{"id":"A32","pred":"ID:","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A33","pred":"ID:","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A34","pred":"ID:","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_137433"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T4","span":{"begin":219,"end":223},"obj":"OrganismTaxon"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T34","span":{"begin":250,"end":253},"obj":"ChemicalEntity"},{"id":"T32","span":{"begin":229,"end":233},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":197,"end":203},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":181,"end":192},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":81,"end":90},"obj":"ChemicalEntity"},{"id":"T70673","span":{"begin":129,"end":142},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T57477","span":{"begin":219,"end":223},"obj":"OrganismTaxon"}],"attributes":[{"id":"A34","pred":"ID:","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_137433"},{"id":"A33","pred":"ID:","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A32","pred":"ID:","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A31","pred":"ID:","subj":"T31","obj":"D016291"},{"id":"A30","pred":"ID:","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_2679"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000661"},{"id":"A28","pred":"ID:","subj":"T28","obj":"ChemicalEntity"},{"id":"A70696","pred":"#label","subj":"T70673","obj":"DISEASE"}],"text":"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))."}